Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Haas

Showing results (361-370 of 542) with videos related to

Pageof 55
Sort By:
Open Forum Infectious Diseases|July 17, 2015
Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for HyperbilirubinemiaSaran Vardhanabhuti, Heather J Ribaudo, Raphael J Landovitz, et al.
Personality Neuroscience|May 6, 2021
Investigating the neural substrates of Antagonistic Externalizing and social-cognitive Theory of Mind: an fMRI examination of functional activity and synchronyBrandon Weiss, Andrew Jahn, Courtland S Hyatt, et al.
The Lancet. Infectious Diseases|November 8, 2017
Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectivesLaurent Abel, Jacques Fellay, David W Haas, et al.
The Journal of Infectious Diseases|August 8, 2009
CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, HaitiPaul Leger, Rebecca Dillingham, Carole Anne Beauharnais, et al.
The Journal of Infectious Diseases|February 26, 2009
Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americansDavid W Haas, Tebeb Gebretsadik, Gail Mayo, et al.
European Journal of Clinical Pharmacology|September 26, 2009
Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitorsTodd Hulgan, John P Donahue, Laura Smeaton, et al.
Clinical Pharmacology and Therapeutics|January 25, 2003
Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapyJohn P Donahue, David Dowdy, Krishna K Ratnam, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|May 1, 1990
Cyclic ovarian function in recreational athletesA Broocks, K M Pirke, U Schweiger, et al.
Pharmacogenetics and Genomics|November 9, 2017
Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuationPaul Leger, Sanika Chirwa, Jacinta N Nwogu, et al.
BMC Psychology|February 5, 2022
Patients' experiences treated with open-label placebo versus double-blind placebo: a mixed methods qualitative studyJulia W Haas, Giulio Ongaro, Eric Jacobson, et al.
Pageof 55

Showing results (361-370 of 542) with videos related to

Sort By:
Pageof 55
Open Forum Infectious Diseases|July 17, 2015
Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for HyperbilirubinemiaSaran Vardhanabhuti, Heather J Ribaudo, Raphael J Landovitz, et al.
Personality Neuroscience|May 6, 2021
Investigating the neural substrates of Antagonistic Externalizing and social-cognitive Theory of Mind: an fMRI examination of functional activity and synchronyBrandon Weiss, Andrew Jahn, Courtland S Hyatt, et al.
The Lancet. Infectious Diseases|November 8, 2017
Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectivesLaurent Abel, Jacques Fellay, David W Haas, et al.
The Journal of Infectious Diseases|August 8, 2009
CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, HaitiPaul Leger, Rebecca Dillingham, Carole Anne Beauharnais, et al.
The Journal of Infectious Diseases|February 26, 2009
Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americansDavid W Haas, Tebeb Gebretsadik, Gail Mayo, et al.
European Journal of Clinical Pharmacology|September 26, 2009
Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitorsTodd Hulgan, John P Donahue, Laura Smeaton, et al.
Clinical Pharmacology and Therapeutics|January 25, 2003
Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapyJohn P Donahue, David Dowdy, Krishna K Ratnam, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|May 1, 1990
Cyclic ovarian function in recreational athletesA Broocks, K M Pirke, U Schweiger, et al.
Pharmacogenetics and Genomics|November 9, 2017
Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuationPaul Leger, Sanika Chirwa, Jacinta N Nwogu, et al.
BMC Psychology|February 5, 2022
Patients' experiences treated with open-label placebo versus double-blind placebo: a mixed methods qualitative studyJulia W Haas, Giulio Ongaro, Eric Jacobson, et al.
Pageof 55